ARS Pharmaceuticals (NASDAQ:SPRY) Full Year 2024 Results

Key Financial Results

• Revenue: US$89.1m (up by US$89.1m from FY 2023).
• Net income: US$8.00m (up from US$54.4m loss in FY 2023).
• Profit margin: 9.0% (up from net loss in FY 2023). The move to profitability was driven by higher revenue.
• EPS: US$0.083 (up from US$0.57 loss in FY 2023).

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

All figures shown in the chart above are for the trailing 12 month (TTM) period

ARS Pharmaceuticals Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates.

Looking ahead, revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are up 21% from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We have a graphic representation of ARS Pharmaceuticals' balance sheet and an in-depth analysis of the company's financial position.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.